Tracer library / [213Bi]Bi-B-B4

[213Bi]Bi-B-B4

Also written as [213Bi]Bi-B-B4
Radionuclide
Bi-213
Modality
—
Production route
—
Stage
Preclinical
Syntheses indexed
0
Gynaecological cancerMultiple myeloma / plasma cell malignanciesOther radioligand therapy

What it is

Compound class
Monoclonal antibody radioimmunoconjugate (anti-CD138 antibody B-B4 labeled with 213Bi)
Target / mechanism
syndecan-1 (CD138) PMID 16203801
Clinical application
Multiple myeloma PMID 10541359
Theranostic pair
—

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [213Bi]Bi-B-B4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 39 (2026-09-27) from a reverse search of the PubMed corpus's own unattached articles (articles that named a real compound not yet in this reference): 3 article(s) found under this name, not yet individually researched. Target/mechanism, clinical application, indications, approval, modality, stage and production route are intentionally left empty. PMIDs: 10541359, 16203801, 26734610. Stage set/updated at stage 39 from PMID 26734610: 'This study aims to first develop alpha-RIT using an anti-CD138 mAb radiolabeled with an alpha-emitter, bismuth-213 ((213)Bi-B-B4) and HIPEC in a nude mouse model'.